Biotricity (US:BTCY) Globenewswireยท2025-02-20 13:15Core Viewpoint - Biotricity Inc. continues to innovate in the healthcare sector with a focus on remote monitoring and diagnostic solutions, achieving significant financial growth and operational efficiency in Q3 FY25 [2][4]. Financial Highlights - Q3 FY25 revenue increased by 21.7% year-over-year to $3.6 million, with recurring Technology-as-a-Service (TaaS) fees rising 21.8% to $3.39 million [6][7]. - Gross profit margin improved to 76.4%, up from 72.9% in the same quarter last year, attributed to better margins on technology fees and efficiencies gained through AI [8][13]. - Net loss decreased by 56.7% year-over-year to $1.32 million, or $0.054 per share, compared to a net loss of $3.05 million, or $0.339 per share, in Q3 FY24 [8][7]. Operational Highlights - The company has monitored billions of heartbeats for atrial fibrillation (AFib), benefiting hundreds of thousands of patients and enabling earlier medical interventions [3]. - Biotricity's AI technology development in remote cardiac care has led to predictive monitoring tools that enhance disease profiling and patient management [4]. - The company maintained a strong customer retention rate and expanded its customer base, now serving hundreds of centers across 35 states [13]. Future Outlook - Management expects continued improvements in cash flow and operational efficiency, with a strong focus on achieving positive cash flow and profitability [7][8]. - The company plans to host a financial results call to discuss Q3 FY25 results and future business updates [10].